Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
Sign up for the iNFOnews newsletter today!
Selecting your primary region ensures you get the stories that matter to you first.
MONTREAL – Researchers at Montreal’s McGill University say a recent study appears to refute the hypothesis that anti-inflammatory drugs could help stop the progression of Alzheimer’s disease.
The school tested the effect of the anti-inflammatory drug naproxen on 200 participants who were at risk of developing the disease but were not yet showing symptoms.
The study’s authors say the two-year clinical trial turned up no evidence that taking the common drug, which is sold under the brand name Aleve, had any effect on the disease’s progression when compared to a placebo.
The school says researchers have known for decades that inflammation accompanies Alzheimer’s brain lesions, which led to the hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs) could help stop or prevent the disease.
But the researchers say subsequent clinical trials all point to the conclusion that the drugs don’t make a difference, regardless of whether the patients are already experiencing cognitive impairment.
Lead author Dr. John Breitner says the results suggest that researchers will have to look elsewhere in their search for a much-needed way to prevent the disease.
News from © iNFOnews.ca, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.